Leerink Partnrs Issues Optimistic Estimate for LXEO Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of Lexeo Therapeutics in a research report issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.82). The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.61) EPS and FY2027 earnings at ($1.61) EPS.

A number of other equities analysts also recently weighed in on the stock. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Royal Bank of Canada lowered their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Chardan Capital lowered their target price on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday. Finally, HC Wainwright lowered their price target on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Lexeo Therapeutics presently has an average rating of "Buy" and an average price target of $18.50.

Lexeo Therapeutics Stock Performance

LXEO stock traded up $0.20 during midday trading on Friday, reaching $2.92. The company had a trading volume of 265,384 shares, compared to its average volume of 716,593. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $3.00 and a 200 day moving average price of $4.55. Lexeo Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The firm has a market capitalization of $96.94 million, a PE ratio of -0.92 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19).

Hedge Funds Weigh In On Lexeo Therapeutics

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its stake in Lexeo Therapeutics by 5.6% in the fourth quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock valued at $333,000 after purchasing an additional 2,677 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Lexeo Therapeutics by 30.1% during the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after buying an additional 3,093 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares during the last quarter. Rhumbline Advisers boosted its stake in Lexeo Therapeutics by 19.6% in the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after acquiring an additional 4,127 shares during the last quarter. Finally, Barclays PLC boosted its stake in Lexeo Therapeutics by 9.9% in the fourth quarter. Barclays PLC now owns 55,161 shares of the company's stock valued at $363,000 after acquiring an additional 4,951 shares during the last quarter. Institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.